Across TCGA pan-cancer cohorts, FXN Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FXN data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher FXN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FXN expression acts as an unfavorable survival marker.
KICH are the cancer types where FXN Mutation most reproducibly stratifies survival.